So close, yet so far: Zogenix LGS trial succeeds, but results underwhelm
Merely crossing the finish line isn’t enough — the win must be decisive. Ask Zogenix, whose experimental seizure drug met the main goal in a pivotal study in patients with Lennox-Gastaut Syndrome (LGS) on Thursday, but saw its shares plummet after the magnitude of the therapy’s effect fell short.
The drug, fenfluramine (to be branded Fintepla) — one-half of the notorious axed prescription weight-loss cocktail fen-phen — was tested against a placebo in 263 patients with the rare, treatment-resistant form of childhood epilepsy. The data comes months after Zogenix’s revamped application was accepted for review in patients with Dravet syndrome, another rare seizure disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.